Abstract 1151P
Background
Cutaneous adnexal tumors comprise a heterogenous group of both benign and malignant tumors evolving from the four primary adnexal structures. Malignant adnexal tumors encompass a variety of histologic subtypes with varying clinical presentation. Due to the rarity of these conditions, incidence and prevalence is not well understood. In a retrospective analysis, estimated five-year Overall Survival (OS) and Disease-Free Survival (DFS) were estimated at 73% and 98%, respectively. There is a paucity of data surrounding the preferred clinical management of cutaneous adnexal tumors due to the rarity of these entities.
Methods
Patients with malignant adnexal tumors were identified using the National Cancer Database (NCDB). We examined demographic, clinicopathologic, and treatment information. Excluded from our cohort were patients with metastatic or unknown disease stage, positive or unknown margin status, unknown radiation and/or chemotherapy status, and unknown vital status. Chi-square analyses were used to assess differences across sebaceous versus non-sebaceous histologies. Multivariable Cox proportional hazard models were used to evaluate the effects of treatment modalities on overall survival after controlling for relevant covariates (age, race, and stage).
Results
3,694 patients were included in the final analysis. The most prevalent malignant cutaneous adnexal tumor included sebaceous carcinoma (n=1699, 46%), eccrine porocarcinoma (n = 568, 15.4%), and skin appendage carcinoma (n =415, 11.2%). In patients with fully resected cutaneous adnexal tumors with negative surgical margins, multivariable results showed that receipt of adjuvant radiation was associated with statistically significantly longer survival compared to not receiving radiation (HR .76 (95%CI 0.61 – 0.96)). Non-sebaceous histology was also associated with longer survival than sebaceous histology (HR 0.78 (95% CI 0.69 – 0.88)). After stratifying by histologic groups, adjuvant radiation was associated with longer overall survival in sebaceous carcinoma (HR 0.62 (95% CI 0.42 – 0.92)), while receipt of adjuvant radiation in non-sebaceous histology groups was not associated with overall survival (HR 0.85 (95% CI 0.65 – 1.13)). Use of adjuvant chemotherapy following R0 resection was not associated with overall survival in the sebaceous group, while in the non-sebaceous group, chemotherapy was associated with shorter overall survival (HR 3.92 (95% CI 1.94 – 7.92)).
Conclusions
Acknowledging the limitations of a retrospective evaluation of real-world data, there does not appear to be a benefit for adjuvant chemotherapy after R0 resection in cutaneous adnexal carcinomas. Alternatively, omission of adjuvant radiotherapy was associated with an increased risk of mortality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1109P - Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Presenter: Lu Si
Session: Poster session 13
1110P - A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma
Presenter: Tu Hu
Session: Poster session 13
1111P - A randomised phase II study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)
Presenter: Avinash Gupta
Session: Poster session 13
1112P - Five-year survival after intermittent targeted therapy and anti-PD1 in stage IV melanoma: An update of the IMPemBra trial
Presenter: Lotte Hoeijmakers
Session: Poster session 13
1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma
Presenter: Dirk Schadendorf
Session: Poster session 13
1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)
Presenter: Ainara Soria Rivas
Session: Poster session 13
1115P - Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
Presenter: Karolina Piejko
Session: Poster session 13
1116P - Long term outcome of complete responders to immune checkpoint inhibitors (ICI) or target therapy (TT) in advanced melanoma
Presenter: Celine Boutros
Session: Poster session 13
1117P - Overall survival (OS) in patients with metastatic BRAF V600-mutant melanoma treated with encorafenib plus binimetinib (ENCO+BINI): Comparing real-world vs clinical trial data
Presenter: Gino In
Session: Poster session 13
1118P - Real-world treatment patterns and outcomes among patients with BRAF+ metastatic melanoma refractory to first-line immunotherapy
Presenter: Thach-Giao Truong
Session: Poster session 13